Akero Therapeutics (AKRO) said late Tuesday it priced an upsized public offering of about 5.3 million shares at $48 each and pre-funded warrants to purchase about 2 million shares at $47.9999 per warrant.
The company anticipates gross proceeds of $350 million.
Underwriters have a 30-day option to acquire up to about 1.1 million additional shares, the company said.
The offering is expected to close on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。